Trial record 2 of 223612 for:    ALL

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients With ECOG Performance Status of 2

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2016 by University of Pittsburgh
Sponsor:
Information provided by (Responsible Party):
Liza Villaruz, MD, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT02879617
First received: July 22, 2016
Last updated: August 22, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2020 (Final data collection date for primary outcome measure)